
### ðŸ«  Lipid Disorders: Hypertriglyceridemia in Secondary ASCVD Prevention

#### âœ… True Statements
1. **Persistently elevated triglycerides** are an independent risk factor for **future adverse cardiovascular events** in patients with **known atherosclerotic cardiovascular disease (ASCVD)**.
2. **Icosapent ethyl**, a purified formulation of **eicosapentaenoic acid (EPA)**, can be added to **statin therapy** for **secondary prevention** of cardiovascular events in patients with **fasting triglyceride levels >150 mg/dL (1.70 mmol/L)**.
3. In the **REDUCE-IT trial**, adding **icosapent ethyl** to statin therapy reduced the risk of **major cardiovascular events** by **25%** compared with placebo.
4. The **U.S. Department of Veterans Affairs/U.S. Department of Defense** guidelines recommend adding **icosapent ethyl** to **maximally tolerated statin therapy** in patients with **elevated triglycerides** and known ASCVD.
5. **Bile acid sequestrants** such as **cholestyramine** are primarily used to **lower LDL cholesterol** and may cause a **modest increase in triglyceride levels**.
6. **Fibrates**, such as **gemfibrozil**, are appropriate for patients with **severe hypertriglyceridemia (triglycerides >500 mg/dL [5.65 mmol/L])** at risk for **acute pancreatitis**, but do **not reduce cardiovascular events** and may increase **myopathy risk** when combined with statins.
7. **Niacin** lowers **triglyceride levels by 25â€“30%** and raises **HDL cholesterol**, but it does **not improve cardiovascular outcomes** beyond statin therapy and is often **poorly tolerated**.

#### ðŸ’¬ Extra
2. Icosapent ethyl is used as an adjunct to statins in patients with elevated triglycerides despite optimal LDL control.
3. The REDUCE-IT trial included patients with ASCVD or diabetes plus other risk factors.
5. Cholestyramine is not appropriate for triglyceride lowering and can worsen hypertriglyceridemia.
6. Gemfibrozil is contraindicated in patients who require ongoing statin therapy due to elevated myopathy risk.
7. Niacin's use is limited by gastrointestinal and flushing side effects.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #LipidDisorders #Hypertriglyceridemia #IcosapentEthyl #SecondaryPrevention #StatinTherapy

#### ðŸ“™ Reference
Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960-993. PMID: 34332805 doi:10.1016/j.jacc.2021.06.011

#### ðŸ†” Question ID
CVMCQ24030

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Dyslipidemia â€” Secondary Prevention of Atherosclerotic Cardiovascular Disease

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **High-intensity statin therapy** should be initiated in patients **aged â‰¤75 years with ASCVD** to achieve a reduction in **LDL cholesterol of â‰¥50%**.
2. If **high-intensity statin therapy** is contraindicated or not tolerated, **moderate-intensity statin therapy** should be initiated to achieve a reduction in **LDL cholesterol of 30% to 49%**.
3. If **LDL cholesterol remains â‰¥70 mg/dL (1.81 mmol/L)** despite maximally tolerated statin therapy, **ezetimibe** should be added.
4. If **LDL cholesterol goals** are still unmet, then a **PCSK9 monoclonal antibody** may be considered.
5. Patients with **multiple major ASCVD events** or **one major ASCVD event plus multiple high-risk conditions** are considered **very high risk** and may benefit from **nonstatin therapies** when LDL goals are unmet.
6. **Bempedoic acid** or **inclisiran** may be considered if LDL goals are not achieved with **statin, ezetimibe, and/or PCSK9 inhibitor** therapy.
7. The **American Diabetes Association (ADA)** recommends **high-intensity statin therapy** for all patients with **ASCVD and diabetes**.
8a. The ADA also supports adding **ezetimibe and/or PCSK9 monoclonal antibodies** if LDL remains **â‰¥55 mg/dL (1.42 mmol/L)** or fails to decline by **â‰¥50%**.
8b. **High-intensity statin therapy** should be initiated in patients **aged â‰¤75 years with ASCVD** to achieve an **LDL cholesterol reduction â‰¥50%**.
9. **Moderate-intensity statin therapy** is recommended for **primary prevention** in patients with **LDL cholesterol â‰¥190 mg/dL (4.92 mmol/L)**, **diabetes mellitus**, or a **10-year cardiovascular disease (CVD) risk â‰¥12%**.
10. **High-intensity statin therapy** is suggested for **higher-risk patients** for **secondary prevention** of cardiovascular events.
11. Adding **ezetimibe** or a **proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor** to **statin therapy** is suggested in **higher-risk patients** for **secondary prevention**.
12. Adding **icosapent ethyl** to statin therapy is suggested for **secondary prevention** in patients with **fasting triglyceride levels >150 mg/dL (1.69 mmol/L)**.
13. **Niacin** is not recommended for **primary or secondary prevention** of cardiovascular disease.
14. **Fibrates** are suggested against for use with statin therapy in **primary or secondary prevention**.
15. **Omega-3 fatty acid supplements** (excluding icosapent ethyl) are suggested against for **primary or secondary prevention** of cardiovascular disease.
16. **Routine lipid monitoring** is suggested against in patients receiving **statin therapy**.

#### ðŸ’¬ Extra
1. The 2018 AHA/ACC guidelines form the basis of this recommendation.
3. Ezetimibe inhibits intestinal cholesterol absorption and is well tolerated.
4. PCSK9 inhibitors significantly reduce LDL but have historically been cost-limiting; prices have recently declined.
5. High-risk conditions include diabetes, hypertension, smoking, or chronic kidney disease.
6. These agents offer newer mechanisms of action for LDL lowering.
8a. These LDL thresholds are more aggressive in diabetes due to higher baseline cardiovascular risk.
10. Higher-risk patients include those with **recent myocardial infarction**, **acute coronary syndrome**, **stroke**, or established **cardiovascular disease** with additional risk factors.
11. Shared decision-making is emphasized for adding ezetimibe or PCSK9 inhibitors in patients willing to intensify therapy.
12. This applies only to patients with **persistently elevated triglycerides** despite statin use, not to the general population.
13. Niacin's adverse effect profile and lack of added benefit over statins limit its clinical use.
14. Fibrates have not shown consistent cardiovascular benefit and may increase adverse effects when combined with statins.
15. Over-the-counter omega-3 supplements lack the clinical trial evidence seen with purified agents like **icosapent ethyl**.
16. Routine monitoring is not required unless there are **changes in clinical status**, **adherence concerns**, or **drug safety issues**.

#### ðŸ”· Tags
#Cardiology #LipidDisorders #StatinTherapy #SecondaryPrevention #PrimaryPrevention #Triglycerides #PCSK9 #Ezetimibe #IcosapentEthyl #VeteransAffairs #Guidelines #Omega3 #Fibrates #Niacin


#### ðŸ—¾ Supplemental Table

<table>
  <caption><strong>Summary of the U.S. Department of Veterans Affairs/U.S. Department of Defense Dyslipidemia Pharmacotherapy Recommendations</strong></caption>
  <thead>
    <tr>
      <th>Recommendation Topic</th>
      <th>Conclusion</th>
    </tr>
  </thead>
  <tbody>
    <tr><td colspan="2"><strong>Primary Prevention</strong></td></tr>
    <tr><td>Moderate-intensity statin therapy for patients with a 10-year CVD risk â‰¥12%, an LDL cholesterol level â‰¥190 mg/dL (4.92 mmol/L), or diabetes mellitus</td><td>Recommended</td></tr>
    <tr><td>Moderate-intensity statin therapy for patients with a 10-year CVD risk between 6% and 12%</td><td>Suggested if patient prefers treatment</td></tr>
    <tr><td>PCSK9 inhibitors</td><td>Recommended against</td></tr>
    <tr><td>Ezetimibe</td><td>No recommendation</td></tr>

    <tr><td colspan="2"><strong>Secondary Prevention</strong></td></tr>
    <tr><td>At least moderate-intensity statin therapy</td><td>Recommended</td></tr>
    <tr><td>High-intensity statin therapy for higher-risk patients<sup>a,b</sup></td><td>Suggested</td></tr>
    <tr><td>Adding ezetimibe to statin therapy for higher-risk patients<sup>a,b</sup></td><td>Suggested</td></tr>
    <tr><td>PCSK9 inhibitor for higher-risk patients<sup>b,c</sup></td><td>Suggested</td></tr>

    <tr><td colspan="2"><strong>Other Medications, Supplements, and Nutraceuticals</strong></td></tr>
    <tr><td>Adding icosapent ethyl to statin therapy for secondary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)</td><td>Suggested</td></tr>
    <tr><td>Niacin for primary or secondary prevention</td><td>Recommended against</td></tr>
    <tr><td>Adding fibrates to statin therapy for primary or secondary prevention</td><td>Suggested against</td></tr>
    <tr><td>Omega-3 fatty acids as dietary supplements for primary or secondary prevention</td><td>Suggested against</td></tr>
    <tr><td>Adding icosapent ethyl to statin therapy for primary prevention in patients with persistently elevated fasting triglyceride levels >150 mg/dL (1.69 mmol/L)</td><td>No recommendation</td></tr>

    <tr><td colspan="2"><strong>Monitoring</strong></td></tr>
    <tr><td>Routine monitoring of lipid levels in patients receiving statin therapy</td><td>Suggested against</td></tr>
  </tbody>
</table>

<p><em>
CVD = cardiovascular disease; PCSK9 = proprotein convertase subtilisin/kexin type 9.<br>
<sup>a</sup> In patients who are willing to intensify treatment after discussing the risk of high-intensity statin therapy.<br>
<sup>b</sup> Higher-risk patients include those with a myocardial infarction or acute coronary syndrome in the past 12 months; recurrent acute coronary syndrome, myocardial infarction, or stroke; or established CVD with additional risk factors (e.g., currently smoking, diabetes, peripheral artery disease, or coronary revascularization).<br>
<sup>c</sup> In patients who are willing to intensify treatment after discussing the uncertain long-term safety and benefits.
</em></p>